These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 10534163)
21. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Erkiliç S; Aydin A; Koçer NE Endocr Pathol; 2002; 13(3):207-11. PubMed ID: 12446919 [TBL] [Abstract][Full Text] [Related]
22. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions. Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of the follicular patterned thyroid lesions based on the WHO 2022 criteria with an emphasis on the grey-zone lesions. Misra S; Dhawan S; Badwal S; Sengupta A; Khosla A; Agarwal SK; Rao S Ann Diagn Pathol; 2024 Aug; 71():152282. PubMed ID: 38522359 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19. Murtezaoglu AR; Gucer H Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974 [TBL] [Abstract][Full Text] [Related]
25. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Sahoo S; Hoda SA; Rosai J; DeLellis RA Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules. Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016 [TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies. Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546 [TBL] [Abstract][Full Text] [Related]
29. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Schelfhout LJ; Van Muijen GN; Fleuren GJ Am J Clin Pathol; 1989 Nov; 92(5):654-8. PubMed ID: 2479256 [TBL] [Abstract][Full Text] [Related]
30. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions]. Tong J; Wang Y; Da JP Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220 [TBL] [Abstract][Full Text] [Related]
31. Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions. Elsers DA; Hussein MRA; Osman MH; Mohamed GA; Hosny G Asian Pac J Cancer Prev; 2021 Oct; 22(10):3365-3376. PubMed ID: 34711014 [TBL] [Abstract][Full Text] [Related]
32. Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: Some insights into their identification. Bizzarro T; Martini M; Capodimonti S; Straccia P; Lombardi CP; Pontecorvi A; Larocca LM; Rossi ED Cancer Cytopathol; 2016 Oct; 124(10):699-710. PubMed ID: 27717284 [TBL] [Abstract][Full Text] [Related]
33. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472 [TBL] [Abstract][Full Text] [Related]
34. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Saleh HA; Jin B; Barnwell J; Alzohaili O Diagn Pathol; 2010 Jan; 5():9. PubMed ID: 20181018 [TBL] [Abstract][Full Text] [Related]
35. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status. Walts AE; Mirocha JM; Bose S J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102 [TBL] [Abstract][Full Text] [Related]
36. Cytopathology of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: A comparative study with similar patterned papillary thyroid carcinoma variants. Mahajan S; Agarwal S; Kocheri N; Jain D; Mathur SR; Iyer VK Cytopathology; 2018 Jun; 29(3):233-240. PubMed ID: 29638022 [TBL] [Abstract][Full Text] [Related]
37. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217 [TBL] [Abstract][Full Text] [Related]
38. Sonographic and cytologic differences of NIFTP from infiltrative or invasive encapsulated follicular variant of papillary thyroid carcinoma: A Review of 179 Cases. Yang GCH; Fried KO; Scognamiglio T Diagn Cytopathol; 2017 Jun; 45(6):533-541. PubMed ID: 28332339 [TBL] [Abstract][Full Text] [Related]
39. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Cameselle-Teijeiro J; Chan JK Mod Pathol; 1999 Apr; 12(4):400-11. PubMed ID: 10229505 [TBL] [Abstract][Full Text] [Related]
40. Role of Ultrasound in Predicting Tumor Invasiveness in Follicular Variant of Papillary Thyroid Carcinoma. Hahn SY; Shin JH; Oh YL; Kim TH; Lim Y; Choi JS Thyroid; 2017 Sep; 27(9):1177-1184. PubMed ID: 28699414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]